Stifel analyst Rick Wise raised the firm’s price target on Boston Scientific to $52 from $50 and keeps a Buy rating on the shares. While the surprising Italian "payment provision" optics complicated the company’s Q4 reported performance, organic performance was "excellent" across all product lines, the analyst tells investors in a research note. The firm added that Boston Scientific has important product launches and multiple potentially-positive data catalysts ahead, and that such factors along with possibly easing macro pressures could help prove initial 2023 guidance conservative.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- Piper remains bullish on Boston Scientific, says guidance likely conservative
- Boston Scientific sees FY23 adjusted EPS $1.86-$1.93, consensus $1.93
- Boston Scientific sees Q1 adjusted EPS 42c-44c, consensus 44c
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
- Boston Scientific reports Q4 adjusted EPS 45c, consensus 47c